 NEW YORK, Feb. 23, 2021 GLOBE NEWSWIRE -- Intercept Pharmaceuticals, Inc. Nasdaq:ICPT, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021. 